Obesity Drug Access
3 articles on Obesity Drug Access, researched and written by the Shotlee Editorial Team from primary sources.
Obesity Drug Coverage Restrictions Force Patients to Pivot
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
5 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
8 min read
Mass. Patients Lose GLP-1 Coverage: $500/Month or Weight Regain Fear
After losing insurance coverage for GLP-1 drugs like Zepbound, Massachusetts patients are grappling with $500 monthly costs or the fear of regaining lost weight. Stories from Tierno, Markert, and others highlight the struggle, as doctors warn of health risks from discontinuation. Discover the coverage changes, patient impacts, and potential paths forward.
5 min read